After 3 years away, BIO marked by first-time handshakes and a drive to survive a bear market’s claws FDA staff reveal flaws with Acadia's 2nd Nuplazid try in Alzheimer's psychosis Outset Medical pauses at-home dialysis shipments, sending stock to all-time low Supreme Court overturns 340B pay cut to hospitals After ulcerative colitis flop, Immunic regains some momentum with multiple sclerosis update CSL Behring clicks with photographer Rankin for a history of hemophilia project Pfizer gives up on Paxlovid in less vulnerable COVID patients after data fail to impress Boston Scientific offers $230M for Korean maker of gastrointestinal and airway stents FTC investigating mental health startup Cerebral's business practices: media report MorphoSys finds a nice, new billion-dollar home for unwanted assets in oncology pivot Amylyx's ALS drug prospect could raise cost concerns, ICER contends Digital pathology player Proscia procures $37M to expand its reach Universal healthcare in U.S. would have saved 212,000 lives, $459B in 2020, study finds Featured Story | By Max Bayer In the three years since BIO's last in-person international conference, the biotech market has seesawed from record growth to a cratering bear market. The trend has left many companies scrambling to shore up cash and ink promising partnerships as they look to withstand gusts of fiscal headwinds. read more |
| |
|---|
|
Top Stories By Angus Liu The FDA is poking holes in Acadia's second try for expanding Nuplazid into a new neurological disorder—and in doing so, the agency has revealed a chasm in the data that the company likely won’t be able to remedy without an additional clinical trial. read more By Andrea Park After kicking off the year by shipping out a record number of its Tablo hemodialysis systems for at-home users, Outset Medical has brought those sales to a screeching halt. read more By Paige Minemyer The Supreme Court on Wednesday unanimously rejected massive payment cuts to hospitals under the 340B drug discount program. The controversial program still has other legal battles to face, though. read more By Nick Paul Taylor Immunic has drummed up some enthusiasm for its multiple sclerosis candidate, highlighting the release of previously published data in a peer-reviewed journal and sharing an update on its next trial to claw back a sliver of the value it lost after its ulcerative colitis flop. read more By Ben Adams CSL Behring teamed up with renowned portrait photographer Rankin to launch “Portraits of Progress,” a project that charts 60 years in the fight against hemophilia. read more By Angus Liu Pfizer’s Paxlovid has proven useful in COVID-19 patients at high risk of severe disease. But the antiviral drug may not help less vulnerable patients, a clinical trial has shown. read more By Andrea Park Boston Scientific is adding a familiar face to its family of medical devices. read more By Heather Landi Mental health startup Cerebral's problems continue to mount as the Federal Trade Commission is now investigating the company's business practices, according to media reports. read more By Annalee Armstrong MorphoSys has found a home for a couple of assets it doesn’t want anymore—a nice billion-dollar home, that is—as the German biotech shifts focus to oncology. read more By Fraiser Kansteiner Just one day after Amylyx Pharmaceuticals’ new amyotrophic lateral sclerosis (ALS) med Albrioza passed muster with Canadian regulators, U.S. watchdog ICER has taken aim at the drug’s cost effectiveness in a new draft report. read more By Conor Hale Shortly after garnering a European green light for its digital pathology platform, the software developer Proscia has posted a $37 million venture capital round, which will also help it seek additional product approvals. read more By Dave Muoio A hypothetical single-payer system would have saved nearly 339,000 lives from COVID-19 and other diseases during the pandemic's first two years while saving hundreds of billions in spending, researchers estimated in a newly published study. read more |
